Autolus Therapeutics (AUTL) Competitors

Autolus Therapeutics (NASDAQ:AUTL) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Is AUTL or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 37.36% compared to Autolus Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	N/A	-56.18%	-29.61%
Catalyst Pharmaceuticals	37.36%	40.78%	35.36%

Do institutionals & insiders have more ownership in AUTL or CPRX?

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, AUTL or CPRX?

Autolus Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Which has higher earnings and valuation, AUTL or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$10.12M	46.02	-$220.66M	-$0.84	-2.08
Catalyst Pharmaceuticals	$491.73M	5.25	$163.89M	$1.65	12.78

Do analysts prefer AUTL or CPRX?

Autolus Therapeutics presently has a consensus target price of $9.12, suggesting a potential upside of 421.14%. Catalyst Pharmaceuticals has a consensus target price of $33.20, suggesting a potential upside of 57.50%. Given Autolus Therapeutics' higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Catalyst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Does the media prefer AUTL or CPRX?

In the previous week, Catalyst Pharmaceuticals had 7 more articles in the media than Autolus Therapeutics. MarketBeat recorded 10 mentions for Catalyst Pharmaceuticals and 3 mentions for Autolus Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 1.10 beat Autolus Therapeutics' score of 0.94 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Catalyst Pharmaceuticals beats Autolus Therapeutics on 12 of the 16 factors compared between the two stocks.